InjuryBoard Philadelphia Archives

• Fish From China Blocked By FDA

  Jamie Sheller | June 28, 2007 5:42 PM | 0 Comments
  Category: Defective & Dangerous Products

  The import of five species of fish from China is being blocked by the FDA. Eel, basa, shrimp, catfish and dace are the species indicated in the alert. The import alert was issued due to reports of contamination with drugs and unsafe food additives. The fish will be blocked until the importer can prove that the seafood is not contaminated. The medications and additives at issue are not...

• FDA Advisory Panel Rejects Weight-Loss Drug

  Jamie Sheller | June 27, 2007 6:05 PM | 0 Comments
  Category: FDA & Prescription Drugs

  The weight-loss drug rimonabant or Zimulti, made by Sanofi-Adventis, has hit a stumbling block in seeking to enter the market. An FDA advisory panel has unanimously voted to reject the drug. Though rimonabant is sold in 18 other countries, the panel found that Sanofi-Adventis had failed to prove the safety of the drug, though it was shown to be effective in weight loss. In studies, twice as...

• Label Changes for RotaTeq

  Jamie Sheller | June 20, 2007 8:09 PM | 0 Comments
  Category: FDA & Prescription Drugs

  Health care professionals were recently alerted to RotaTeq label changes. RotaTeq is a vaccine given to infants to prevent illness from the rotavirus. The ADVERSE REACTIONS and POST-MARKETING sections of the RotaTeq prescribing information were changed to reflect cases of Kawasaki disease. Kawasaki disease has not been shown to be caused by RotaTeq or any vaccine. Typically, Kawasaki...

• New Safety Warnings Ordered for Avandia

  Jamie Sheller | June 08, 2007 7:02 PM | 0 Comments
  Category: FDA & Prescription Drugs

  Following an analysis iindicating increased cardiovascular risks with use of Avandia, the FDA is ordering a new safety label for the drug. Advandia is used to treat diabetes. In May 2007 The New England Journal of Medicine published a meta-analysis showiing that use of Avandia was tied to an increased risk of myocardial infarction. Shortly after that publication, the FDA sought the label...